Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Precirix, a Belgium-based precision radiopharmaceuticals developer spun out of Vrije Universiteit Brussel, closed an €80m ($88m) series B round today backed by V-Bio Ventures, the venture capital firm aligned with research institute VIB. The round was co-led by Inkef Capital, Jeito Capital and Forbion, and additionally included pharmaceutical firm Novo as well as Gimv, HealthCap, Pontifax Venture Capital, BioMed Partners, and all seed-stage investors, of which only Fournier-Majoie Foundation was previously identified. Precirix raised $42m in series A…